Diabetes Therapeutics Market is Segmented By Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), By Therapy Type (Oral Antidiabetics,Injectable Antidiabetics, Others), By End User (Hospitals and Clinics, Homecare, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Diabetes Therapeutics Market Size
The Global Diabetes Therapeutics Market reached USD 61.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 106.2 million by 2031. The Global Diabetes Therapeutics Market is expected to exhibit a CAGR of 7.2% during the forecast period 2024-2031.
Oral drugs, including type 2 diabetics, can take a variety of classes of oral medications to assist in controlling their blood sugar levels. These consist of metformin enhances insulin sensitivity and reduces hepatic glucose synthesis.
Sulfonylureas stimulate the pancreas to make more insulin. DPP-4 blockers by preventing the breakdown of incretin hormones, aid in lowering blood sugar levels. SGLT2 blockers By boosting urine glucose excretion and lower blood sugar levels. Agonists of the GLP-1 receptor encourage the synthesis of insulin and inhibit the release of glucagon.
Diabetes Therapeutics Market Summary
|
Metrics |
Details |
|
CAGR |
7.2% |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Type, Therapy Type, End-user, and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other Surgery key Insights. |
For more insights Request Free Sample
Diabetes Therapeutics Market Dynamics
The Increasing Prevalence of Diabetes is Driving the Global Diabetes Therapeutics Market Growth
The global prevalence of diabetes, both type 1 and type 2, has steadily risen. According to IDF Diabetes Atlas (2021), 783 million adults, or one in eight, would have diabetes by 2045, a 46% rise; 10.5% of adults (20–79 years) have diabetes and nearly half are completely ignorant that they have the disease.
Type 2 diabetes, caused by socioeconomic, demographic, environmental, and hereditary variables, affects more than 90% of diabetics. Urbanization, population aging, declining levels of physical activity, and rising rates of overweight and obesity are the main causes of type 2 diabetes.
Technological Advancements are Driving the Global Diabetes Therapeutics Market Growth
Innovative technology has led to improvements in the treatment of diabetes over time. Various technologies are currently available that can assist in managing diabetes. The optimal glucose management solution will change as technology develops and depend on individual tastes.
The majority of diabetics will frequently check their blood glucose levels throughout the day. Various kinds of glucose meters are readily available. The recommended target level and how frequently persons with diabetes need to check their blood sugar vary from person to person.
Side Effects Associated With Diabetes Therapeutics are Hampering the Global Diabetes Therapeutics Market Growth
The common side effects of include gastrointestinal issues such as nausea, diarrhea, or stomach discomfort. In rare cases, it can cause lactic acidosis, a serious condition. Sulfonylurea’s Side effects can include low blood sugar (hypoglycemia), weight gain, and gastrointestinal disturbances. DPP-4 inhibitors’ potential side effects may include upper respiratory tract infections, headaches, and gastrointestinal issues. SGLT2 inhibitor’s side effects can include genital yeast infections, urinary tract infections, increased urination, and dehydration.
Diabetes Therapeutics Market Segment Analysis
The Global Diabetes Therapeutics Market is segmented based on type, therapy type, end-user, and region.
The Oral Antidiabetics Segment Is Expected To Hold A Dominant Position In The Market
The oral antidiabetics segment accounted for the highest market stake, accounting for approximately 43.5% of the diabetes therapeutics market in 2022. As per the article published in StatPearls 2023, the most successful care of diabetes mellitus necessitates an interdisciplinary strategy that includes pharmacologic therapy when appropriate to achieve specific glycemic objectives and dietary and exercise adjustments.
Lifestyle changes must be supplemented with oral pharmaceuticals for the best glycemic management, significantly as type 2 diabetes mellitus advances with continuous loss of pancreatic beta-cell activity and insulin production. Examples including sulfonylureas (glipizide, glyburide, gliclazide, glimepiride) meglitinides (repaglinide and nateglinide), biguanides (metformin), thiazolidinediones (rosiglitazone, pioglitazone) and more.
Source: DataM Intelligence Analysis (2023)
Global Diabetes Therapeutics Market Geographical Share
North America Holds a Dominant Position in the Global Diabetes Therapeutics Market
North America is estimated to hold around 37.6% of the total market share throughout the forecast period. Owing to the aging population in the region increasing, active market players are boosting regional growth over the forecast period. For instance, in October 2022, Teplizumab was sold in the United States due to a co-promotion service agreement between Sanofi US and Provention Bio, Inc.
Teplizumab is an investigational anti-CD3 monoclonal antibody created by Prevention that is being tested for the prevention of clinical type 1 diabetes (T1D) in people who are at risk as determined by the presence of two or more T1D-related autoantibodies. Teplizumab would be the first-ever disease-modifying treatment for T1D if it were approved by the U.S. Food and Drug Administration (FDA).
Source: DataM Intelligence Analysis (2023)
Diabetes Therapeutics Market Companies
The major global players in the market include Abbott India Ltd, Novo Nordisk, AstraZeneca, Pfizer, Eli Lilly, Dr. Reddy`s Labs, Sanofi, Novartis International, Merck, and Boehringer Ingelheim among others.
Russia Ukraine Conflict Analysis
The Russia-Ukraine war may affect the diabetes therapeutics market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. There may be population relocation and disruption of healthcare services in areas that are immediately impacted by the conflict.
Accessing healthcare facilities, such as diabetic clinics, and getting the essential drugs and treatments may become difficult as a result. Displaced people may find it challenging to continue their usual diabetes treatment regimen, which could have an adverse effect on their general health and well-being.
Artificial Intelligence Analysis
Artificial intelligence (AI) is increasingly being used in the diabetes therapeutics market to improve various aspects of the customer experience. The discovery and development of novel diabetes medications can benefit from AI analysis.
AI systems can find prospective therapeutic targets, forecast drug efficacy, and quicken the drug discovery process by analyzing enormous volumes of data, including genomic details, molecular structures, and clinical trial outcomes. This may result in the creation of novel treatments and drugs for the control of diabetes.
Key Developments
- In April 2023, Aspect Biosystems and Novo Nordisk A/S agreed to create bioprinted tissue therapeutics that are intended to replace, repair, or supplement biological functions within the body in order to produce a new class of truly disease-modifying treatments for diabetes and obesity.
- In March 2023, Sanofi agreed to purchase Provention Bio, in accordance with an agreement reached with Provention Bio, Inc., a publicly traded biopharmaceutical company with a U.S. base that specializes in detecting and treating immune-mediated illnesses like type 1 diabetes (T1D).
Why Purchase the Report?
- To visualize the Global Diabetes Therapeutics Market segmentation based on the type, therapy type, end-user, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of diabetes therapeutics market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Diabetes Therapeutics Market Report Would Provide Approximately 61 Tables, 57 Figures And 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
